Secondary Raynaud’s phenomenon (RP) is a severe vascular complication associated with connective tissue diseases, particularly systemic sclerosis (SSc).
It affects 15–20% of patients with SSc (about 0.5–1 million people in the U.S.), mainly women aged 30–60. The condition causes chronic pain and disability, yet current treatments offer only symptomatic relief. There is a significant unmet need for therapies that prevent or reverse vascular damage, particularly in populations overlapping with SSc and pulmonary arterial hypertension.
Screening of a vast library using SAR, DMPK, and in vitro / in vivo selection.
Highly selective antagonist with required bioavailability.
Favorable toxicity results.
We are advancing our candidate through formulation.
